{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:46:15Z","timestamp":1791920775414,"version":"4.3.4"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Symptomatic thrombosis is a clinically important complication of asparaginase-containing therapy in children with acute lymphoblastic leukemia (ALL), but reported incidence and predictors vary across studies. We conducted a systematic review and meta-analysis to estimate its incidence and synthesize reported predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>PubMed, Embase, Web of Science Core Collection, Scopus, and the Cochrane Library were searched from inception through April 15, 2026. Eligible studies enrolled patients aged \u226421 years with ALL receiving asparaginase-containing therapy and reported extractable incidence or predictor data for overall symptomatic thrombosis or symptomatic venous thromboembolism. Proportions were pooled after logit transformation using a random-effects model. Predictor data were synthesized narratively when quantitative pooling was inappropriate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-three studies met the eligibility criteria; 15 studies involving 17,809 children and 655 events contributed to the incidence meta-analysis. The pooled incidence of symptomatic thrombosis was 5.6% (95% CI: 3.5%-9.0%), with substantial heterogeneity (I\u00b2=96.9%). Study-specific estimates ranged from \u223c1% to 22.7%. Older age was the most consistently reported predictor; associations with inherited thrombophilia, non-O blood group, high-risk treatment status, and T-ALL phenotype were inconsistent across cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Symptomatic thrombosis affects \u223c6% of children with ALL receiving asparaginase-containing therapy, although incidence varies considerably across studies. Older age was the most reproducible risk factor, whereas evidence for other predictors remains heterogeneous.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003307","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:00:40Z","timestamp":1791918040000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and Predictors of Symptomatic Thrombosis During Asparaginase-containing Therapy in Children With Acute Lymphoblastic Leukemia"],"prefix":"10.1097","author":[{"given":"Chong","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanjuan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"R1-20261013","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"R2-20261013","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"R3-20261013","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"key":"R4-20261013","doi-asserted-by":"crossref","first-page":"828702","DOI":"10.3389\/fped.2022.828702","article-title":"Thrombosis complications in pediatric acute lymphoblastic leukemia: risk factors, management, and prevention: is there any role for pharmacologic prophylaxis?","volume":"10","author":"Rodriguez","year":"2022","journal-title":"Front Pediatr"},{"key":"R5-20261013","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"key":"R6-20261013","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3324\/haematol.2024.285702","article-title":"Acute therapy-related toxicities in pediatric acute lymphoblastic leukemia","volume":"110","author":"Birenboim","year":"2025","journal-title":"Haematologica"},{"key":"R7-20261013","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2006-04-015511","article-title":"Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients","volume":"108","author":"Caruso","year":"2006","journal-title":"Blood"},{"key":"R8-20261013","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bjh.15112","article-title":"BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy","volume":"180","author":"Sibson","year":"2018","journal-title":"Br J Haematol"},{"key":"R9-20261013","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jth.14671","article-title":"The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH","volume":"18","author":"Zwicker","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R10-20261013","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Brit Med J"},{"key":"R12-20261013","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2141.2005.05528.x","article-title":"Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease","volume":"129","author":"Athale","year":"2005","journal-title":"Br J Haematol"},{"key":"R13-20261013","doi-asserted-by":"crossref","first-page":"e26938","DOI":"10.1002\/pbc.26938","article-title":"Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: a prospective evaluation","volume":"65","author":"Athale","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20261013","doi-asserted-by":"crossref","first-page":"e29581","DOI":"10.1002\/pbc.29581","article-title":"Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: results from Dana-Farber Cancer Institute ALL Consortium trial 05-001","volume":"69","author":"Athale","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"R15-20261013","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.3390\/cancers12102759","article-title":"Venous thromboembolism and its risk factors in children with acute lymphoblastic leukemia in Israel: a population-based study","volume":"12","author":"Barzilai-Birenboim","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R16-20261013","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1055\/s-2008-1046624","article-title":"Thrombosen bei Kindern mit akuter lymphoblastischer Leuk\u00e4mie unter dem COALL-Protokoll [Thrombosis in children with acute lymphoblastic leukemia treated with the COALL protocol]","volume":"206","author":"Eckhof-Donovan","year":"1994","journal-title":"Klin Padiatr"},{"key":"R17-20261013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/08880018.2022.2089791","article-title":"Incidence and risk factors of venous thromboembolism in childhood acute lymphoblastic leukaemia - a population-based analysis of the Austrian Berlin-Frankfurt-M\u00fcnster (BFM) study group","volume":"40","author":"Gidl","year":"2023","journal-title":"Pediatr Hematol Oncol"},{"key":"R18-20261013","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"Grace","year":"2011","journal-title":"Br J Haematol"},{"key":"R19-20261013","first-page":"1079","article-title":"T-immunophenotype is associated with an increased prevalence of thrombosis in children with acute lymphoblastic leukemia. A retrospective study","volume":"88","author":"Giordano","year":"2003","journal-title":"Haematologica"},{"key":"R20-20261013","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/rth2.12182","article-title":"Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: risk factors and effect on prognosis","volume":"3","author":"Klaassen","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"R21-20261013","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.thromres.2019.04.011","article-title":"Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia","volume":"178","author":"Mateos","year":"2019","journal-title":"Thromb Res"},{"key":"R22-20261013","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-2008-1043791","article-title":"Low rate of severe venous thromboses in children with ALL treatment according to COALL-92 and -97 protocol","volume":"211","author":"Mauz-K\u00f6rholz","year":"1999","journal-title":"Klin Padiatr"},{"key":"R23-20261013","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1055\/s-0037-1613930","article-title":"Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols)","volume":"83","author":"Mauz-K\u00f6rholz","year":"2000","journal-title":"Thromb Haemost"},{"key":"R24-20261013","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/pbc.25515","article-title":"L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: impact on thrombotic and infectious events in children with acute lymphoblastic leukemia","volume":"62","author":"Merlen","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R25-20261013","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1182\/blood-2010-01-263012","article-title":"Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study","volume":"115","author":"Mitchell","year":"2010","journal-title":"Blood"},{"key":"R26-20261013","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood.V93.5.1595","article-title":"Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors","volume":"93","author":"Nowak-G\u00f6ttl","year":"1999","journal-title":"Blood"},{"key":"R27-20261013","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0049-3848(01)00286-9","article-title":"Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase\/prednisone administration","volume":"103","author":"Nowak-G\u00f6ttl","year":"2001","journal-title":"Thromb Res"},{"key":"R28-20261013","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2002-06-1901","article-title":"Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration","volume":"101","author":"Nowak-G\u00f6ttl","year":"2003","journal-title":"Blood"},{"key":"R29-20261013","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ajh.27171","article-title":"Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: a report from CYP-C","volume":"99","author":"Pelland-Marcotte","year":"2024","journal-title":"Am J Hematol"},{"key":"R30-20261013","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2018.02.150","article-title":"Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia","volume":"165","author":"Prasca","year":"2018","journal-title":"Thromb Res"},{"key":"R31-20261013","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/jth.15699","article-title":"Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013","volume":"20","author":"Ruiz-Llobet","year":"2022","journal-title":"J Thromb Haemost"},{"key":"R32-20261013","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/1076029611412366","article-title":"Inherited prothrombotic risk factors in Turkish children with acute lymphoblastic leukemia: significance of concomitant genetic mutation","volume":"18","author":"Torun","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"key":"R33-20261013","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jth.13236","article-title":"Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study","volume":"14","author":"Tuckuviene","year":"2016","journal-title":"J Thromb Haemost"},{"key":"R34-20261013","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s11684-022-0958-6","article-title":"Venous thromboembolism in children with acute lymphoblastic leukemia in China: a report from the Chinese Children\u2019s Cancer Group-ALL-2015","volume":"17","author":"Yin","year":"2023","journal-title":"Front Med"},{"key":"R35-20261013","doi-asserted-by":"crossref","first-page":"902117","DOI":"10.3389\/fped.2022.902117","article-title":"Current use of asparaginase in acute lymphoblastic leukemia\/lymphoblastic lymphoma","volume":"10","author":"Maese","year":"2022","journal-title":"Front Pediatr"},{"key":"R36-20261013","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","article-title":"American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism","volume":"2","author":"Monagle","year":"2018","journal-title":"Blood Adv"},{"key":"R37-20261013","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-024-01178-5","article-title":"Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen","volume":"14","author":"Shimony","year":"2024","journal-title":"Blood Cancer J"},{"key":"R38-20261013","doi-asserted-by":"crossref","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"R39-20261013","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"key":"R40-20261013","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"Brit Med J"},{"key":"R41-20261013","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/sim.7140","article-title":"Random effects meta-analysis: coverage performance of 95% confidence and prediction intervals following REML estimation","volume":"36","author":"Partlett","year":"2017","journal-title":"Stat Med"},{"key":"R42-20261013","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.20.03692","article-title":"Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001","volume":"39","author":"Vrooman","year":"2021","journal-title":"J Clin Oncol"},{"key":"R44-20261013","first-page":"53","article-title":"Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries","volume":"109","author":"Zheng","year":"2024","journal-title":"Haematologica"},{"key":"R45-20261013","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.2019001847","article-title":"Treatment of venous thromboembolism in pediatric patients","volume":"135","author":"Witmer","year":"2020","journal-title":"Blood"},{"key":"R46-20261013","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/bloodadvances.2024015328","article-title":"American Society of Hematology\/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients","volume":"9","author":"Monagle","year":"2025","journal-title":"Blood Adv"},{"key":"R47-20261013","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1182\/bloodadvances.2025019415","article-title":"ASH ISTH 2026 guidelines for anticoagulant prophylaxis of pediatric patients at risk of venous thromboembolism","volume":"10","author":"Betensky","year":"2026","journal-title":"Blood Adv"},{"key":"R48-20261013","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood Adv"},{"key":"R49-20261013","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.3390\/jcm10163692","article-title":"The impact of ABO blood type on developing venous thromboembolism in cancer patients: systematic review and meta-analysis","volume":"10","author":"Urabe","year":"2021","journal-title":"J Clin Med"},{"key":"R50-20261013","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.2023022920","article-title":"Classification and risk stratification in T-lineage acute lymphoblastic leukemia","volume":"145","author":"P\u00f6l\u00f6nen","year":"2025","journal-title":"Blood"},{"key":"R51-20261013","first-page":"3019","article-title":"How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults","volume":"141","author":"Si Lim","year":"2023","journal-title":"Blood"},{"key":"R52-20261013","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3324\/haematol.2018.194175","article-title":"THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents","volume":"104","author":"Greiner","year":"2019","journal-title":"Haematologica"},{"key":"R53-20261013","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.thromres.2020.02.015","article-title":"Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia - time to reconsider current approaches?","volume":"188","author":"Fulcher","year":"2020","journal-title":"Thromb Res"},{"key":"R54-20261013","doi-asserted-by":"crossref","first-page":"e2020042325","DOI":"10.1542\/peds.2020-042325","article-title":"A real-time risk-prediction model for pediatric venous thromboembolic events","volume":"147","author":"Walker","year":"2021","journal-title":"Pediatrics"},{"key":"R55-20261013","doi-asserted-by":"crossref","first-page":"e2337789","DOI":"10.1001\/jamanetworkopen.2023.37789","article-title":"Model-guided decision-making for thromboprophylaxis and hospital-acquired thromboembolic events among hospitalized children and adolescents: the CLOT Randomized Clinical Trial","volume":"6","author":"Walker","year":"2023","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:00:46Z","timestamp":1791918046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003307"}},"subtitle":["A Meta-analysis and Narrative Synthesis"],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":53,"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003307","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"2026-07-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}